Market Insights
Growth in healthcare investments, the prevalence of angioedema, and a growing high-risk geriatric population are the major factors driving the global market growth for angioedema treatment. In the next few years, the demand for angioedema treatment is expected to increase significantly in economies such as China and Japan. The rising incidence of hereditary angioedema and high awareness about treatment and the management of angioedema together drive the global hereditary angioedema market.
The treatments studied for analyzing the overall angioedema treatment market are antihistamines, corticosteroids, autoimmunity drugs, antifibrinolytic agents, and blood protein controllers. The market size and forecast for each of these segments for the period 2014–2022 are provided in this study, along with respective CAGRs for the forecast period 2016–2022. This report also highlights information about major clinical trial candidates under scrutiny for angioedema treatment. These candidates are categorized corresponding to their trial phases, namely phases I, II, and III.
Geographically, the global angioedema treatment market is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2014–2022. Market growth rates for the forecast period 2016–2022 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global angioedema treatment market. Tools such as the market positioning of key players and attractive investment propositions provide the readers with insights into the competitive scenario of the global angioedema treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the angioedema treatment market.
Based on the type of treatment, the global angioedema treatment market is segmented as follows:
- Antihistamines
- Corticosteroid
- Autoimmune Drugs
- Antifibrinolytic Agents
- Blood protein controllers
Angioedema, also known as angioneurotic edema, is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa, and submucosal tissues. Angioedema is a common condition caused by allergies and shows up as sudden swelling under the skin surface. Angioedema can be caused by allergies to food, medications, environmental factors, genetic reasons, and common allergens. There are four common forms of angioedema, such as allergic angioedema, idiopathic angioedema, drug-induced angioedema, and hereditary angioedema. The treatments for angioedema include a normal physical examination and proper drugs for the prevention of attacks in the patients. The drugs’ treatments include antihistamines, corticosteroids, autoimmunity drugs, antifibrinolytic agents, and blood protein controllers. Antihistamines and corticosteroids accounted for approximately 45%–50% of the total market share because these are the first-line therapies preferred by medical practitioners and majorly used as supportive therapies and the most accessible source of treatment across the globe.
For the purpose of this study, the global angioedema treatment market is categorized as follows:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
The geographical segmentation of the global market for angioedema treatment comprises North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. In the base year 2015, North America accounted for the largest market in the angioedema treatment market due to the rising number of angioedema patients in the U.S. along with the rising awareness among the patients, which are the key factors contributing towards the growth of the angioedema treatment market in this region. In North America, an estimated 20% of the population is affected by angioedema. Contemporary medical management of angioedema is divided between the treatment of acute attacks and short- and long-term prophylaxis to reduce both the frequency and severity of subsequent flare-ups.
Worldwide, the incidence of angioedema is approximately 1 in 30,000 to 50,000 persons. Europe held the second-largest market in the angioedema treatment market. The high prevalence rate of angioedema in Europe is the driving factor for the growth of the market. Moreover, the rising government initiative to increase awareness regarding angioedema would further grow the market in Europe. Asia Pacific is expected to be the fastest-growing market in the global angioedema market due to rising prevalence rates in countries like Japan, China, and others. Moreover, the growing research and development in the drug discovery of angioedema would further drive the market during the forecast period.
